- Medtech player Anteris Technologies (AVR) has locked its shares up ahead of a capital raise announcement
- The trading halt will be lifted once a formal announcement is made concerning the raise on or before December 29
- While the company has not clarified what the funds will be used for, it has some exciting projects in the pipeline
- Anteris’ heart valve technology, DurAVR is currently undergoing studies against leading market competitors and is showing promising results
- The raise also comes on the back of a significant win at the PCR London Valves conference 2020, where it was chosen as best innovation for the year
- AVR shares last traded at $3.75 prior to the trading halt
Medtech player Anteris Technologies (AVR) has locked its shares up ahead of a capital raise announcement.
The trading halt will be lifted once a formal announcement is made concerning the raise on or before December 29. A company statement indicates there is no other information to disclose to the market.
While the company has not clarified what the funds will be used for, it has some exciting projects in the pipeline. Namely, the ongoing testing of its heart valve technology, DurAVR.
Interim data from a series of head-to-head studies between the DurAVR 3D single-piece aortic valve and other leading competitors have put Anteris in a solid position to secure Food and Drug Administration (FDA) approval.
The raise also comes on the back of a significant win at the PCR London Valves conference 2020, where the valve was chosen as best innovation for the year.
AVR shares last traded at $3.75 prior to the trading halt.